Summary

Viral Vectors-Based Gene Therapy for Non-Human Primates Market – Scope of Report
TMR’s report on the global viral vectors-based gene therapy for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors-based gene therapy for non-human primates market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors-based gene therapy for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the viral vectors-based gene therapy for non-human primates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors-based gene therapy for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors-based gene therapy for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors-based gene therapy for non-human primates market.

The report delves into the competitive landscape of the global viral vectors-based gene therapy for non-human primates market. Key players operating in the global viral vectors-based gene therapy for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors-based gene therapy for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors-based gene therapy for non-human primates Market Report
• What is the sales/revenue generated by viral vectors-based gene therapy for non-human primates across all regions during the forecast period?
• What are the opportunities in the global viral vectors-based gene therapy for non-human primates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Viral Vectors-Based Gene Therapy for Non-Human Primates Market – Research Objectives and Research Approach
The comprehensive report on the global viral vectors-based gene therapy for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors-based gene therapy for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors-based gene therapy for non-human primates market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Viral Vectors-based Gene Therapy for Non-human Primates Market
4. Market Overview
    4.1. Introduction
        4.1.1. Vector Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, 2020-2034
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Recent Advancements in Viral Vectors Technology
    5.2. List of Leading CROs offering Non-human Primates based Preclinical Testing Services
    5.3. PORTER’s Analysis on Viral Vectors for Non-human Primates Industry
    5.4. Key Shortlisting Metrics for End-users
    5.5. Regional Distribution of Non-human Primate Preclinical Studies
    5.6. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
    5.7. Impact of COVID-19 Pandemic on Viral Vectors for Non-human Primates Industry
6. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Vector Type, 2020-2034
        6.3.1. Adenoviral Vectors
        6.3.2. Adeno-associated Vectors
        6.3.3. Retroviral Vectors
        6.3.4. Lentiviral Vectors
        6.3.5. Other Vectors
    6.4. Market Attractiveness By Vector Type
7. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primate
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
        7.3.1. Marmosets
        7.3.2. Rhesus Macaques
        7.3.3. Cynomolgus Monkey
        7.3.4. Others
    7.4. Market Attractiveness By Type of Non-human Primate
8. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Technology
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By Technology, 2020-2034
        8.3.1. Genetic Disorders
        8.3.2. Infectious Diseases
        8.3.3. Oncological Disorders
        8.3.4. Neurodegenerative Disorders
        8.3.5. Other Disorders
    8.4. Market Attractiveness By Technology
9. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Region
    9.1. Key Findings
    9.2. Market Value Forecast By Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness By Country/Region
10. North America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast By Vector Type, 2020-2034
        10.2.1. Adenoviral Vectors
        10.2.2. Adeno-associated Vectors
        10.2.3. Retroviral Vectors
        10.2.4. Lentiviral Vectors
        10.2.5. Other Vectors
    10.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
        10.3.1. Marmosets
        10.3.2. Rhesus Macaques
        10.3.3. Cynomolgus Monkey
        10.3.4. Others
    10.4. Market Value Forecast By Technology, 2020-2034
        10.4.1. Genetic Disorders
        10.4.2. Infectious Diseases
        10.4.3. Oncological Disorders
        10.4.4. Neurodegenerative Disorders
        10.4.5. Other Disorders
    10.5. Market Value Forecast By Country, 2020-2034
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Vector Type
        10.6.2. By Type of Non-human Primate
        10.6.3. By Technology
        10.6.4. By Country
11. Europe Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Vector Type, 2020-2034
        11.2.1. Adenoviral Vectors
        11.2.2. Adeno-associated Vectors
        11.2.3. Retroviral Vectors
        11.2.4. Lentiviral Vectors
        11.2.5. Other Vectors
    11.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
        11.3.1. Marmosets
        11.3.2. Rhesus Macaques
        11.3.3. Cynomolgus Monkey
        11.3.4. Others
    11.4. Market Value Forecast By Technology, 2020-2034
        11.4.1. Genetic Disorders
        11.4.2. Infectious Diseases
        11.4.3. Oncological Disorders
        11.4.4. Neurodegenerative Disorders
        11.4.5. Other Disorders
    11.5. Market Value Forecast By Country, 2020-2034
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Vector Type
        11.6.2. By Type of Non-human Primate
        11.6.3. By Technology
        11.6.4. By Country
12. Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Vector Type, 2020-2034
        12.2.1. Adenoviral Vectors
        12.2.2. Adeno-associated Vectors
        12.2.3. Retroviral Vectors
        12.2.4. Lentiviral Vectors
        12.2.5. Other Vectors
    12.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
        12.3.1. Marmosets
        12.3.2. Rhesus Macaques
        12.3.3. Cynomolgus Monkey
        12.3.4. Others
    12.4. Market Value Forecast By Technology, 2020-2034
        12.4.1. Genetic Disorders
        12.4.2. Infectious Diseases
        12.4.3. Oncological Disorders
        12.4.4. Neurodegenerative Disorders
        12.4.5. Other Disorders
    12.5. Market Value Forecast By Country, 2020-2034
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Vector Type
        12.6.2. By Type of Non-human Primate
        12.6.3. By Technology
        12.6.4. By Country
13. Latin America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Vector Type, 2020-2034
        13.2.1. Adenoviral Vectors
        13.2.2. Adeno-associated Vectors
        13.2.3. Retroviral Vectors
        13.2.4. Lentiviral Vectors
        13.2.5. Other Vectors
    13.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
        13.3.1. Marmosets
        13.3.2. Rhesus Macaques
        13.3.3. Cynomolgus Monkey
        13.3.4. Others
    13.4. Market Value Forecast By Technology, 2020-2034
        13.4.1. Genetic Disorders
        13.4.2. Infectious Diseases
        13.4.3. Oncological Disorders
        13.4.4. Neurodegenerative Disorders
        13.4.5. Other Disorders
    13.5. Market Value Forecast By Country, 2020-2034
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Vector Type
        13.6.2. By Type of Non-human Primate
        13.6.3. By Technology
        13.6.4. By Country
14. Middle East & Africa Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Vector Type, 2020-2034
        14.2.1. Adenoviral Vectors
        14.2.2. Adeno-associated Vectors
        14.2.3. Retroviral Vectors
        14.2.4. Lentiviral Vectors
        14.2.5. Other Vectors
    14.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
        14.3.1. Marmosets
        14.3.2. Rhesus Macaques
        14.3.3. Cynomolgus Monkey
        14.3.4. Others
    14.4. Market Value Forecast By Technology, 2020-2034
        14.4.1. Genetic Disorders
        14.4.2. Infectious Diseases
        14.4.3. Oncological Disorders
        14.4.4. Neurodegenerative Disorders
        14.4.5. Other Disorders
    14.5. Market Value Forecast By Country, 2020-2034
        14.5.1. GCC
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Vector Type
        14.6.2. By Type of Non-human Primate
        14.6.3. By Technology
        14.6.4. By Country
15. Competition Landscape
    15.1. Market Player - Competition Matrix (By Tier and Size of companies)
    15.2. Company Profiles
        15.2.1. CRISPR Therapeutics AG
            15.2.1.1. Company Overview
            15.2.1.2. Financial Overview
            15.2.1.3. Product Portfolio
            15.2.1.4. Business Strategies
            15.2.1.5. Recent Developments
        15.2.2. Voyager Therapeutics, Inc.
            15.2.2.1. Company Overview
            15.2.2.2. Financial Overview
            15.2.2.3. Product Portfolio
            15.2.2.4. Business Strategies
            15.2.2.5. Recent Developments
        15.2.3. Sarepta Therapeutics, Inc.
            15.2.3.1. Company Overview
            15.2.3.2. Financial Overview
            15.2.3.3. Product Portfolio
            15.2.3.4. Business Strategies
            15.2.3.5. Recent Developments
        15.2.4. Neuracle Genetics
            15.2.4.1. Company Overview
            15.2.4.2. Financial Overview
            15.2.4.3. Product Portfolio
            15.2.4.4. Business Strategies
            15.2.4.5. Recent Developments
        15.2.5. Beacon Therapeutics
            15.2.5.1. Company Overview
            15.2.5.2. Financial Overview
            15.2.5.3. Product Portfolio
            15.2.5.4. Business Strategies
            15.2.5.5. Recent Developments
        15.2.6. REGENXBIO Inc.
            15.2.6.1. Company Overview
            15.2.6.2. Financial Overview
            15.2.6.3. Product Portfolio
            15.2.6.4. Business Strategies
            15.2.6.5. Recent Developments
        15.2.7. 4D Molecular Therapeutics
            15.2.7.1. Company Overview
            15.2.7.2. Financial Overview
            15.2.7.3. Product Portfolio
            15.2.7.4. Business Strategies
            15.2.7.5. Recent Developments
        15.2.8. Rocket Pharmaceuticals, Inc.
            15.2.8.1. Company Overview
            15.2.8.2. Financial Overview
            15.2.8.3. Product Portfolio
            15.2.8.4. Business Strategies
            15.2.8.5. Recent Developments